Variant form of urate oxidase and use thereof

Details Variant form of urate oxidase and use thereof Variant form of urate oxidase and use thereof

2006-04-11

2010-10-12

Nashed, Nashaat T (Department: 1656)

Chemistry: molecular biology and microbiology

Enzyme , proenzyme; compositions thereof; process for...

Oxidoreductase

C435S181000

Reexamination Certificate

active

07811800

ABSTRACT:
The present invention relates to genetically modified proteins with uricolytic activity. More specifically, the invention relates to proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidases.

REFERENCES:
patent: 3451996 (1969-06-01), Sumyk et al.
patent: 3616231 (1971-10-01), Bergmeyer et al.
patent: 3931399 (1976-01-01), Bohn et al.
patent: 4141973 (1979-02-01), Balazs
patent: 4169764 (1979-10-01), Takezawa et al.
patent: 4179337 (1979-12-01), Davis et al.
patent: 4297344 (1981-10-01), Schwinn et al.
patent: 4301153 (1981-11-01), Rosenberg
patent: 4312979 (1982-01-01), Takemoto et al.
patent: 4317878 (1982-03-01), Nakanishi et al.
patent: 4421650 (1983-12-01), Nagasawa et al.
patent: 4425431 (1984-01-01), Takemoto et al.
patent: 4445745 (1984-05-01), Cartesse
patent: 4460575 (1984-07-01), d'Hinterland et al.
patent: 4460683 (1984-07-01), Gloger et al.
patent: 4485176 (1984-11-01), Bollin, Jr. et al.
patent: 4753796 (1988-06-01), Moreno et al.
patent: 4766106 (1988-08-01), Katre et al.
patent: 4797474 (1989-01-01), Patroni et al.
patent: 4847325 (1989-07-01), Shadle et al.
patent: 4917888 (1990-04-01), Katre et al.
patent: 4945086 (1990-07-01), Benitz et al.
patent: 4966963 (1990-10-01), Patroni
patent: 4987076 (1991-01-01), Takashio et al.
patent: 4992531 (1991-02-01), Patroni et al.
patent: 5008377 (1991-04-01), Patroni et al.
patent: 5010183 (1991-04-01), Macfarlane
patent: 5283317 (1994-02-01), Saifer et al.
patent: 5286637 (1994-02-01), Veronese et al.
patent: 5362641 (1994-11-01), Fuks et al.
patent: 5382518 (1995-01-01), Caput et al.
patent: 5428128 (1995-06-01), Mensi-Fattohi et al.
patent: 5458135 (1995-10-01), Patton et al.
patent: 5468478 (1995-11-01), Saifer et al.
patent: 5529915 (1996-06-01), Phillips et al.
patent: 5541098 (1996-07-01), Caput et al.
patent: 5567422 (1996-10-01), Greenwald
patent: 5612460 (1997-03-01), Zalipsky
patent: 5624903 (1997-04-01), Muller et al.
patent: 5633227 (1997-05-01), Muller et al.
patent: 5637749 (1997-06-01), Greenwald
patent: 5643575 (1997-07-01), Martinez et al.
patent: 5653974 (1997-08-01), Hung et al.
patent: 5766897 (1998-06-01), Braxton
patent: 5811096 (1998-09-01), Aleman et al.
patent: 5880255 (1999-03-01), Delgado et al.
patent: 5919455 (1999-07-01), Greenwald et al.
patent: 5929231 (1999-07-01), Malkki et al.
patent: 5932462 (1999-08-01), Harris et al.
patent: 5948668 (1999-09-01), Hartman et al.
patent: 5955336 (1999-09-01), Shigyo et al.
patent: 6201110 (2001-03-01), Olsen et al.
patent: 6468210 (2002-10-01), Iliff
patent: 6475143 (2002-11-01), Iliff
patent: 6524241 (2003-02-01), Iliff
patent: 6527713 (2003-03-01), Iliff
patent: 6569093 (2003-05-01), Iliff
patent: 6576235 (2003-06-01), Williams et al.
patent: 6608892 (2003-08-01), Shaffer et al.
patent: 6783965 (2004-08-01), Sherman et al.
patent: 6913915 (2005-07-01), Ensor et al.
patent: 7056713 (2006-06-01), Hershfield et al.
patent: 2002/0010319 (2002-01-01), Ansaldi et al.
patent: 2003/0082786 (2003-05-01), Ensor et al.
patent: 2003/0166249 (2003-09-01), Williams et al.
patent: 2005/0014240 (2005-01-01), Sherman et al.
patent: 2007/0274977 (2007-11-01), Hartman et al.
patent: 2008/0159976 (2008-07-01), Hartman et al.
patent: 2009/0169534 (2009-07-01), Hartman et al.
patent: 2009/0317889 (2009-12-01), Fischer et al.
patent: 279 486 (1990-06-01), None
patent: 0055188 (1982-06-01), None
patent: 0408 461 (1991-01-01), None
patent: 1 100 542 (2001-05-01), None
patent: 55-99189 (1980-07-01), None
patent: 62-55079 (1987-03-01), None
patent: 03-148298 (1991-06-01), None
patent: 09-154581 (1997-06-01), None
patent: 333148 (1994-09-01), None
patent: 365606 (1998-03-01), None
patent: 369838 (2003-09-01), None
patent: 488848 (2005-05-01), None
patent: 318706 (2007-04-01), None
patent: WO8604145 (1986-07-01), None
patent: WO 94/19007 (1994-09-01), None
patent: WO94/23735 (1994-10-01), None
patent: WO9511987 (1995-05-01), None
patent: WO96/23064 (1996-08-01), None
patent: WO 98/31383 (1998-07-01), None
patent: WO 00/07629 (2000-02-01), None
patent: WO 00/08196 (2000-02-01), None
patent: WO 01/59078 (2001-08-01), None
patent: WO03045436 (2003-06-01), None
Yamamoto et al., 1996, J. Biochem., vol. 119, pp. 80-84.
Kelly, S. J., M. Delnomdedieu, et al. (2001) as “Diabetes insipidus in uricase-deficient mice: A model for evaluating therapy with poly(ethylene glycol)-modified uricase.” in J Am Soc Nephrol 12: 1001-1009.
Office Action dated Oct. 30, 2009, U.S. Appl. No. 11/539,475, filed Oct. 6, 2006, Inventor Jacob Hartman.
Office Action dated Jun. 25, 2009, U.S. Appl. No. 11/539,475, filed Oct. 6, 2006, Inventor Jacob Hartman.
Office Action dated Oct. 30, 2009, U.S. Appl. No. 11/899,688, filed Sep. 7, 2007, Inventor Jacob Hartman.
Sundy, J.S. et al., A Phase I Study of Pegylated-Uricase (Puricase®) in Subjects with Gout, Arthritis Rheum. 2004 vol. 50, supplement 9, S337-338.
Sundy, J.S. et al., A Phase I Study of Pegylated-Uricase (Puricase®) in Subjects with Gout, presented at American College of Rheumatology Annual Scientific Meeting on Oct. 16-21, 2004 at San Antonio, TX, Poster 807.
Ganson, N.J. et al., Antibodies to Polyethylene Glycol (PEG) during Phase I Investigation of PEG-Urate Oxidase (PEG-uricase; Puricase®) for Refractory Gout, Arthritis Rheum. 2004 vol. 50, supplement 9, S338.
Ganson, N.J. et al., Antibodies to Polyethylene Glycol (PEG) during Phase I Investigation of PEG-Urate Oxidase (PEG-uricase; Puricase®) for Refractory Gout, presented at American College of Rheumatology Annual Scientific Meeting on Oct. 16-21, 2004 at San Antonio, TX, Poster 808.
Baraf H. et al., Resolution Of Tophi With Intravenous Peg-uricase In Refractory Gout, Arthritis & Rheumatism, 2005, Sep. Supplement, vol. 52, No. 9, p. S105.
Baraf H. et al., Resolution Of Tophi With Intravenous Peg-uricase in Refractory Gout, presented at American College of Rheumatology 2005 Annual Scientific Meeting on Nov. 13-17, 2005 at San Diego, CA, Poster 194.
Sundy, J.S. et al., A Phase 2 Study of Multiple Doses of Intravenous Polyethylene Glycol (PEG)-uricase in Patients with Hyperuricemia and Refractory Gout, presented at American College of Rheumatology 2005 Annual Scientific Meeting on Nov. 13-17, 2005 at San Diego, CA, #1836.
Abuchowski, A., et al. “Effect of Covalent Attachment of Polyethylene Glycol on Immunogenicity and Cirulating Life of Bovine Liver Catalase.” J. Biol. Chem. 252-:3582-3586, American Society for Biochemistry and Molecular Biology (1977).
Abuchowski, A., et al., “Reduction of Plasma Urate Levels in the Cockerel with Polyethylene Glycol-Uricase,” J. Pharmacol. Exp. Ther. 219:352-354, The American Society for Pharmacology and Experimental Therapeutics (1981).
Alvares, K., et al., “The Nucleotide Sequence of a Full Length cDNA Clone Encoding Rat Liver Urate Oxidase,” Biochem. Biophys. Res. Commun. 158:991-995, Academic Press, Inc. (1989).
Alvares, K., et al., “Rat urate oxidase produced by recombinant baculovirus expression: Formation of peroxiscome crystallized core-like structures,” Proc. Natl. Acad. Sci. USA 89:4908-4912, National Academy Of Sciences (1992).
Braun, A. And Alsenz, J., “Development and Use of Enzyme-Linked Immunosorbent Assays (ELISA) for the Detection of Protein Aggregates in Interferon-Alpha (IFN-α) Formulations,” Pharm. Res. 14:1394-1400, Plenum Publishing Corporation (Oct. 1997).
Braun, A., et al. “Protein Aggregates Seem to Play a Key Role Among the Parameters Influencing theAntigenicity of Interferon Alpha (IFN-α) in Normal and Transgenic Mice,” Pharm. Res. 14:1472-1478, Plenum Publishing Corporation (Oct. 1997).
Burnham, N.L., “Polymers for delivering peptides and proteins,” Am. J. Hosp. Pharm. 51:210-218, American Society of Hospital Pharmacists, Inc. (1994).
Caliceti, P., et al., “Biopharmaceutical Properties of Uricase Conjugated to Neutral and Amphiphilic Polymers,” Bioconjugate Chem. 10:639-646, American Chemical Soc

Affiliated with

Also associated with

Rating

Variant form of urate oxidase and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Variant form of urate oxidase and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Variant form of urate oxidase and use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4171291